Author:
Nguyen Holly M.,Ruppender Nazanin,Zhang Xiaotun,Brown Lisha G.,Gross Ted S.,Morrissey Colm,Gulati Roman,Vessella Robert L.,Schimmoller Frauke,Aftab Dana T.,Corey Eva
Publisher
Public Library of Science (PLoS)
Reference44 articles.
1. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;FM Yakes;Mol Cancer Ther,2011
2. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer;WK You;Cancer Res,2011
3. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial;DC Smith;J Clin Oncol,2013
4. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors;B Sennino,2012
5. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer;R Kurzrock;J Clin Oncol,2011
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献